CN101709042A - Aseptic arginine glutamate and preparation method of powder injection thereof - Google Patents
Aseptic arginine glutamate and preparation method of powder injection thereof Download PDFInfo
- Publication number
- CN101709042A CN101709042A CN200910259679A CN200910259679A CN101709042A CN 101709042 A CN101709042 A CN 101709042A CN 200910259679 A CN200910259679 A CN 200910259679A CN 200910259679 A CN200910259679 A CN 200910259679A CN 101709042 A CN101709042 A CN 101709042A
- Authority
- CN
- China
- Prior art keywords
- arginine
- aseptic
- glutamate
- distilled water
- glutamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to aseptic arginine glutamate and a preparation method of powder injection thereof, comprising the following steps: 1) arginine is added in distilled water, after the arginine is completely dissolved, glutamic acid is added, and then the mixture is stirred to lead to react, the reaction is carried out until the solution is clarified, and then aseptic filtration is carried out; 2) the temperature of the filtrate is slowly reduced to be 10-15 DEG C, and then absolute alcohol with 1-3 times of volume of distilled water is added in the filtrate, the mixture is slowly stirred to be crystallized; 3) filtration and crystal vacuum drying are carried out to obtain the aseptic arginine glutamate; 4) the aseptic arginine glutamate is sub-packaged according to specification, so as to obtain the powder injection of the arginine glutamate. Compared with the prior art, in the preparation method of the arginine glutamate, the reaction of the arginine and the glutamic acid is single-step salifying reaction, the reaction process is short, the operation is simple, reaction time is not high, the alcohol can be recycled, and the preparation is easy to industrial production; in addition, the reaction yield is high, the prepared arginine glutamate has high water solubility, the product has good quality and the stability is good.
Description
Technical field
The present invention relates to the synthetic field of pharmaceutical chemistry, specifically, relate to the preparation method of a kind of aseptic arginine glutamate and powder injection thereof.
Background technology
Liver is a body of gland maximum in the human body, also is maximum digestive gland.Liver has the decomposition of carrying out sugar, store glycogen, detoxifcation, secretion of bile and engulf function such as defence.Also has hemopoietic function period the embryo.Human liver function grievous injury can cause ammonia metabolism disorder in the body, causes hyperammonemia state in the body, and the human body vitals are produced infringement (as causing hepatogenic encephalopathy).Glutargin is L-glutamic acid and arginic double salt, smart L-glutamic acid can resolve into arginine and L-glutamic acid in vein input body, wherein arginine participates in bird acid circulation in human body, promote the formation of urea, make the ammonia that produces in the human body, be transformed into nontoxic urea through urea cycle, by discharging in the urine; And too much ammonia is combined into nontoxic glutamine in L-glutamic acid and the blood, and the latter dissociates ammonia through the effect of glutamine enzyme at kidney, is discharged by urine.Arginine and L-glutamic acid effect combination can be removed the hyperammonemia state quickly and effectively, avoid producing serious organ injury.In addition, arginine and L-glutamic acid are the amino acid to the human body beneficial, have the effect of liver protecting, can recover impaired liver function, strengthen the human immunological competence.
Therefore, the Glutargin related drugs is mainly used in treatment because of the hyperammonemia due to acute and chronic hepatopathy such as liver cirrhosis, fatty liver, the hepatitis, is specially adapted to the releasing of the central nervous system symptom that causes because of liver disease and the rescue of hepatic coma.Specifically, the disease and the situation that are suitable for mainly comprise: hepatic coma, hepatogenic encephalopathy, liver cirrhosis merge hepatitis B virus tire continue to increase, liver cirrhosis merge hepatitis C virus tire continue to increase, liver cirrhosis merges ascites, liver cirrhosis merges gestation, liver cirrhosis concurrent infection, liver cirrhosis surgical operation, acute, chronic hepatitis, fatty liver, shock, stupor, alcoholism, and neurosurgery, bone surgery, hepatobiliary surgery, bone gut surgery, burn are performed the operation etc.
At present, produce Glutargin and powder injection thereof both at home and abroad and mainly adopt following two kinds of methods:
Arginine and L-glutamic acid is water-soluble 1., dissolving, filtration, filtrate decompression concentrates, and gets the arginine glutamic acid composition; And then composition is dissolved in 1～5 times the water for injection, stirring and dissolving under 60～90 ℃ of temperature regulate the pH value, and then after filtration, filtrate was left standstill 12～48 hours, room temperature cooling, crystallization, drying, pulverizing, packing.Obviously, in the aforementioned production method, need in the preparation of compositions to carry out concentrating under reduced pressure, increased the energy consumption of producing; In addition, step such as the preparation of powder injection also needs loaded down with trivial details dissolving, filters, leaves standstill, cooling, crystallization, this has increased production cost undoubtedly, has reduced production efficiency.
2. arginine and L-glutamic acid are water-soluble, and 5 ℃ add anhydrous methanol down, carry out repeatedly recrystallization to get Glutargin, and 60 ℃ of vacuum-dryings prepare Glutargin finished product (US2851482) then.This patent mainly contains following two point defects:
2.1. this method uses anhydrous methanol to separate out Glutargin; as everyone knows; methyl alcohol has intensive toxicity; intake toxic reaction will occur when surpassing 4g; wrongly taking a cuvette surpasses 10 grams and just can cause and lose the sight of both eyes; in large-scale production, brought a difficult problem, and the price of methyl alcohol is also quite expensive to environmental protection.In addition, arginine glutamic acid uses the arginine glutamic acid injection of methyl alcohol preparation for a long time as injection usefulness, can toxicity symptom might occur because of dissolvent residual.
2.2. this method need be carried out recrystallization repeatedly, needs a large amount of anhydrous methanols to come crystallization, this has increased production cost undoubtedly and has reduced production efficiency.Therefore present method is not suitable for the suitability for industrialized production Glutargin.
Therefore, be necessary to propose simple to operation, the Glutargin that production energy consumption is low and the preparation method of powder injection thereof.
Summary of the invention
The purpose of this invention is to provide simple to operation, the aseptic arginine glutamate that production energy consumption is low and the preparation method of powder injection thereof.
The preparation method of aseptic arginine glutamate of the present invention comprises: 1) under 25～40 ℃ condition, arginine is joined in the distilled water, treat that arginine dissolves fully after, add L-glutamic acid, stirring makes its reaction, after question response to solution is clarified, and sterile filtration; 2) filtrate slowly is cooled to 10～15 ℃, adds the dehydrated alcohol of 1～3 times of distilled water volume then in filtrate, slowly stirred crystallization; 3) filter, crystal vacuum-drying promptly gets aseptic arginine glutamate.
In addition, can with filtrate 40～50 ℃ the time concentrating under reduced pressure to reclaim ethanol, with the ethanol recycle.
Wherein, in the step 1), described arginine and described L-glutamic acid are 1: 1～1.1 in molar ratio; The mass volume ratio of described arginine and distilled water is 1: 5.5～7.5 (being that every 1g arginine adds 5.5～7.5ml distilled water); The described normal pressure that is reflected at carries out;
In step 2) in comprise that also the temperature of crystallisation process control filtrate is 10～15 ℃;
Step 2) in, the described crystalline time is 1.5～3 hours;
In step 3), described vacuum-drying is 50～70 ℃ of vacuum-dryings 3～6 hours with crystal.
The present invention also provides the preparation method of aseptic arginine glutamate powder injection.This method need not Glutargin is further processed, and only need specify the packing of specification to get final product.
The preparation method of aseptic arginine glutamate powder injection of the present invention comprises: 1) under 25～40 ℃ condition, arginine is joined in the distilled water, treat that arginine dissolves fully after, add L-glutamic acid, stirring makes its reaction, after question response to solution is clarified, and sterile filtration; 2) filtrate slowly is cooled to 10～15 ℃, adds the dehydrated alcohol of 1～3 times of distilled water volume then in filtrate, slowly stirred crystallization; 3) filter, crystal vacuum-drying promptly gets aseptic arginine glutamate; 4) aseptic arginine glutamate is undertaken aseptic subpackaged by specification, promptly get the powder injection of Glutargin.
Wherein, in the step 1), the mol ratio of described arginine and described L-glutamic acid is 1: 1～1.1; The mass volume ratio of described arginine and distilled water is 1: 5.5～7.5 (being that every 1g arginine adds 5.5～7.5ml distilled water); The described normal pressure that is reflected at carries out;
In step 2) in comprise that also the temperature of crystallisation process control filtrate is 10～15 ℃;
Step 2) in, the described crystalline time is 1.5～3 hours;
In step 3), described vacuum-drying is 50～70 ℃ of vacuum-dryings 3～6 hours with crystal.
Compared with prior art, among the preparation method of Glutargin of the present invention, arginine and L-glutamic acid are a step salt-forming reaction, and reaction process is short, simple to operate, temperature of reaction does not need too high, and ethanol is recyclable to be utilized again, is easy to suitability for industrialized production, and reaction yield height, the Glutargin foreign matter content of preparation is few, purity height, constant product quality; And during preparation arginine glutamic acid powder injection, need not Glutargin is carried out aftertreatment, only need specify the aseptic subpackaged of specification to get final product.
Embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
The 40.0g arginine is dissolved in the 220ml distilled water, under agitation condition, adds 33.8g L-glutamic acid in the time of 40 ℃ and make its reaction, treat the solution clarification, through sterile filtration; Add the 440ml dehydrated alcohol when filtrate slowly is cooled to 10 ℃, insulation was slowly stirred 3 hours; Crystallization is the back suction filtration fully, and crystal gets aseptic arginine glutamate 72.3g 60 ℃ of vacuum-dryings 6 hours, and total recovery is about 98.0%.
Quality product meets national standard fully.Aseptic arginine glutamate is through the aseptic subpackaged injection arginine glutamic acid powder injection that promptly gets then.
Detected result sees Table 1.
Embodiment 2
The 80.0g arginine is dissolved in the 480ml distilled water, under agitation condition, adds 74.3g L-glutamic acid in the time of 35 ℃ and make its reaction, treat the solution clarification, through sterile filtration; Add the 500ml dehydrated alcohol when slowly being cooled to 12 ℃, insulation was slowly stirred 1.5 hours; Crystallization is the back suction filtration fully, and crystal gets aseptic arginine glutamate 146.6g 70 ℃ of vacuum-dryings 3.5 hours, and total recovery is about 95.0%.
Quality product meets national standard fully.Aseptic arginine glutamate is through the aseptic subpackaged injection arginine glutamic acid powder injection that promptly gets then.
Detected result sees Table 1.
Embodiment 3
The 100.0g arginine is dissolved in the 750ml distilled water, under agitation condition, adds 90g L-glutamic acid in the time of 25 ℃ and make its reaction, treat the solution clarification, through sterile filtration; Add the 800ml dehydrated alcohol when slowly being cooled to 14 ℃, insulation was slowly stirred 2.5 hours; Crystallization is the back suction filtration fully, and crystal gets aseptic arginine glutamate 179.5g 55 ℃ of vacuum-dryings 5 hours, and total recovery is about 94.5%.
Quality product meets national standard fully.Aseptic arginine glutamate is through the aseptic subpackaged injection arginine glutamic acid powder injection that promptly gets then.
Detected result is attached to see Table 1:
The detected result of the product of table 1 embodiment preparation
| Glutargin | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| ??pH | ??6.45 | ??6.58 | ??6.55 |
| Specific optical rotation | ??+28.50 | ??+29.35 | ??+28.40 |
| Transmittance | ??98.5％ | ??98.6％ | ??99.0％ |
| Muriate | ??0.11％ | ??0.08％ | ??0.10％ |
| Ammonium salt | ??0.01％ | ??0.01％ | ??0.012％ |
| Vitriol | ??0.01％ | ??0.009％ | ??0.075％ |
| Molysite | ??2.50ppm | ??2.55ppm | ??3.01ppm |
| Heavy metal | ??3.50ppm | ??3.75ppm | ??3.74ppm |
| Glutargin | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| Arsenic salt | ??0.01ppm | ??0.05ppm | ??0.02ppm |
| Moisture content | ??3.2％ | ??2.7％ | ??2.6％ |
| Scorching hot residue | ??0.13％ | ??0.05％ | ??0.03％ |
| Content | ??99.5％ | ??99.4％ | ??99.0％ |
| Fusing point | ??193.2～194.3℃ | ??193.2～194.5℃ | ??193.4～194.5℃ |
By the result of table 1 as seen, the foreign matter content of prepared according to the methods of the invention aseptic arginine glutamate and powder injection thereof is few, the purity height, and constant product quality, its performance is considerably beyond domestic and international existing aseptic arginine glutamate and powder injection product thereof.
Claims (10)
1. the preparation method of an aseptic arginine glutamate may further comprise the steps: 1) under 25～40 ℃ condition, arginine is joined in the distilled water, after treating that arginine dissolves fully, add L-glutamic acid, stir and make its reaction, after question response to solution is clarified, sterile filtration; 2) filtrate slowly is cooled to 10～15 ℃, adds the dehydrated alcohol of 1～3 times of distilled water volume then in filtrate, slowly stirred crystallization; 3) filter, crystal vacuum-drying promptly gets aseptic arginine glutamate.
2. the method for claim 1 is characterized in that, in the step 1), the mol ratio of described arginine and described L-glutamic acid is 1: 1～1.1.
3. the method for claim 1 is characterized in that, the mass volume ratio of described arginine and distilled water is 1: 5.5～7.5.
4. the method for claim 1 is characterized in that, the described normal pressure that is reflected at carries out.
5. the method for claim 1 is characterized in that, in step 2) in comprise that also the temperature of crystallisation process control filtrate is 10～15 ℃.
6. the method for claim 1 is characterized in that step 2) in, the described crystalline time is 1.5～3 hours.
7. the method for claim 1 is characterized in that, in step 3), described vacuum-drying is 50～70 ℃ of vacuum-dryings 3～6 hours with crystal.
8. the preparation method of an aseptic arginine glutamate powder injection may further comprise the steps: 1) under 25～40 ℃ condition, arginine is joined in the distilled water, after treating that arginine dissolves fully, add L-glutamic acid, stir and make its reaction, after question response to solution is clarified, sterile filtration; 2) filtrate slowly is cooled to 10～15 ℃, adds the dehydrated alcohol of 1～3 times of distilled water volume then in filtrate, slowly stirred crystallization; 3) filter, crystal vacuum-drying promptly gets aseptic arginine glutamate; 4) aseptic arginine glutamate is undertaken aseptic subpackaged by specification, promptly get the powder injection of Glutargin.
9. method as claimed in claim 8 is characterized in that, in the step 1), the mol ratio of described arginine and described L-glutamic acid is 1: 1～1.1; The mass volume ratio of described arginine and distilled water is 1: 5.5～7.5; The described normal pressure that is reflected at carries out.
10. method as claimed in claim 8 is characterized in that step 2) in, the described crystalline time is 1.5～3 hours; In step 3), described vacuum-drying is 50～70 ℃ of vacuum-dryings 3～6 hours with crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910259679 CN101709042B (en) | 2009-12-22 | 2009-12-22 | Aseptic arginine glutamate and preparation method of powder injection thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910259679 CN101709042B (en) | 2009-12-22 | 2009-12-22 | Aseptic arginine glutamate and preparation method of powder injection thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101709042A true CN101709042A (en) | 2010-05-19 |
| CN101709042B CN101709042B (en) | 2012-07-04 |
Family
ID=42401853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910259679 Active CN101709042B (en) | 2009-12-22 | 2009-12-22 | Aseptic arginine glutamate and preparation method of powder injection thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101709042B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102531969A (en) * | 2011-12-28 | 2012-07-04 | 蚌埠丰原医药科技发展有限公司 | Method for preparing sterile L-arginine |
| CN102603576A (en) * | 2011-12-27 | 2012-07-25 | 开封制药(集团)有限公司 | Preparation method of medicinal arginine glutamate |
| CN112679370A (en) * | 2020-12-30 | 2021-04-20 | 无锡晶海氨基酸股份有限公司 | Preparation method of medicinal arginine glutamic acid |
| CN112778164A (en) * | 2021-01-04 | 2021-05-11 | 无锡晶海氨基酸股份有限公司 | Method for efficiently producing medicinal arginine glutamic acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851482A (en) * | 1957-05-20 | 1958-09-09 | Gen Mills Inc | L-arginine-l-glutamate |
| CN101156842A (en) * | 2007-09-29 | 2008-04-09 | 北京和为康医药科技有限公司 | Pharmaceutical preparation containing arginine glutamic acid |
-
2009
- 2009-12-22 CN CN 200910259679 patent/CN101709042B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603576A (en) * | 2011-12-27 | 2012-07-25 | 开封制药(集团)有限公司 | Preparation method of medicinal arginine glutamate |
| CN102531969A (en) * | 2011-12-28 | 2012-07-04 | 蚌埠丰原医药科技发展有限公司 | Method for preparing sterile L-arginine |
| CN112679370A (en) * | 2020-12-30 | 2021-04-20 | 无锡晶海氨基酸股份有限公司 | Preparation method of medicinal arginine glutamic acid |
| CN112679370B (en) * | 2020-12-30 | 2023-07-18 | 无锡晶海氨基酸股份有限公司 | Preparation method of medicinal arginine glutamic acid |
| CN112778164A (en) * | 2021-01-04 | 2021-05-11 | 无锡晶海氨基酸股份有限公司 | Method for efficiently producing medicinal arginine glutamic acid |
| CN112778164B (en) * | 2021-01-04 | 2022-05-06 | 无锡晶海氨基酸股份有限公司 | Method for efficiently producing medicinal arginine glutamic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101709042B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101709042B (en) | Aseptic arginine glutamate and preparation method of powder injection thereof | |
| CN102153585A (en) | Synthesis method of minodronate midbody and synthesis of minodronate | |
| CN101880240B (en) | Ornithine and aspartate compound and novel method thereof | |
| CN102249974B (en) | Preparation method of (s)-4-hydroxy-2-oxo-1-pyrrolidineacetamide | |
| US8680329B2 (en) | Process for preparation of α-ketoglutaric acid | |
| CN110683970B (en) | Method for removing sodium sulfate solid impurities from taurine | |
| CN102718829B (en) | The preparation method of TUDCANa | |
| CN112552167B (en) | Preparation method of calcium gluconate | |
| CN108358929A (en) | Refining method of tofacitinib citrate | |
| CN109134287B (en) | Purification method of byproduct sodium chloride in betaine or betaine hydrochloride production | |
| EP2613778B1 (en) | Process for the production of l-carnitine tartrate | |
| CN102367243A (en) | Stable potassium sodium dehydroandroan drographolide succinate compound and pharmaceutical composition thereof | |
| CN108017561B (en) | Method for refining carglutamic acid | |
| CN104592053B (en) | A kind of industrialized process for preparing of high-purity sodium pantothenate | |
| CN108383745B (en) | Preparation method of aceclofenac | |
| CN102382072A (en) | Method for refining D-cycloserine | |
| CA2556659A1 (en) | Direct process for the production of the dihydrochloride of an amino acid | |
| CN110669091A (en) | Method for purifying ursodeoxycholic acid | |
| CN114591203A (en) | Preparation method of high-purity creatine | |
| CN110938020B (en) | Preparation process of lauroyl arginine ethyl ester hydrochloride | |
| CN106349145A (en) | Method for preparing intelligence-improving medicine (S)-oxiracetam | |
| CN110655535A (en) | Purification method of tenofovir | |
| CN103159818B (en) | Hyodeoxycholic acid refining method | |
| CN111362821A (en) | Environment-friendly and efficient levodopa production method | |
| CN110028493B (en) | Argatroban refining method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |